Peter Greenleaf
2017 - Avalo Therapeutics
In 2017, Peter Greenleaf earned a total compensation of $29.1K as Former Chief Executive Officer at Avalo Therapeutics.
Compensation breakdown
| Other | $29,136 |
|---|---|
| Total | $29,136 |
Greenleaf received $29.1K in other compensation, accounting for 100% of the total pay in 2017.
Rankings
In 2017, Peter Greenleaf's compensation ranked 14,583rd out of 14,666 executives tracked by ExecPay.
| Classification | Ranking | Percentile |
|---|---|---|
All | 14,583 out of 14,666 | 1st |
Division Manufacturing | 5,736 out of 5,772 | 1st |
Major group Chemicals And Allied Products | 2,064 out of 2,075 | 1st |
Industry group Drugs | 1,720 out of 1,731 | 1st |
Industry Pharmaceutical Preparations | 1,325 out of 1,333 | 1st |
Source: SEC filing on June 19, 2019.
Greenleaf's colleagues
We found five more compensation records of executives who worked with Peter Greenleaf at Avalo Therapeutics in 2017.
2017
Uli Hacksell
Avalo Therapeutics
Chief Executive Officer
2017
Ronald Marcus
Avalo Therapeutics
Chief Medical Officer
2017
John Kaiser
Avalo Therapeutics
Chief Executive Officer
2017
Mariam Morris
Avalo Therapeutics
Chief Financial Officer
2017
Robert Moscato
Avalo Therapeutics
Chief Operating Officer
News
Aurinia Pharmaceuticals CEO Peter Greenleaf's 2021 pay falls 88% to $1.2M
April 18, 2022
Aurinia Pharmaceuticals CEO Peter Greenleaf's 2020 pay jumps 1,353% to $11M
May 10, 2021
Avalo Therapeutics Chairman Simon Pedder's 2019 pay jumps 13,562% to $3.8M
April 28, 2020
Avalo Therapeutics CEO Peter Greenleaf's 2018 pay jumps 17,372% to $5.1M
June 19, 2019